Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
AssigneesInserm, Universite Paris Diderot—Paris 7
InventorsAnne Joutel, Søren Christensen, Thorleif Jan Pedersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.
Claims25
A method of preventing or treating inward remodelling and reduced myogenic tone of brain arteries in a subject in need thereof comprising
- administering to the subject an effective amount of an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2.
(canceled)
9-10. (canceled)
A method of eliciting antibodies capable of binding a Notch3ECD deposit in a subject in need thereof, comprising,
- administering to the subject an effective amount of a vaccine comprising:
- (A) amino acids 40-1643 of human Notch3 (SEQ ID NO:
- 3) or a fragment thereof;
- (B) amino acids 657-846 of human Notch3 (SEQ ID NO 7) or a fragment thereof;
- or
- (C) (A) and (B).
(canceled)
18-19. (canceled)
A pharmaceutical composition comprising
- i) an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2;
- or
- ii) a vaccine comprising:
- (A) amino acids 40-1643 of human Notch3 (SEQ ID NO:
- 3) or a fragment thereof;
- (B) amino acids 657-846 of human Notch3 (SEQ ID NO 7) or a fragment thereof;
- or
- (C) (A) and (B).
A composition comprising
- i) an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2, and a physiologically acceptable carrier;
- or
- ii) (A) amino acids 40-1643 of human Notch3 (SEQ ID NO:
- 3) or a fragment thereof;
- (B) amino acids 657-846 of human Notch3 (SEQ ID NO 7) or a fragment thereof;
- or
- (C) (A) and (B);
- and a physiologically acceptable carrier.
A vaccine comprising:
- (A) amino acids 40-1643 of human Notch3 (SEQ ID NO:
- 3) or a fragment thereof;
- (B) amino acids 657-846 of human Notch3 (SEQ ID NO 7) or a fragment thereof;
- or
- (C) (A) and (B).
Dependencies are inferred from the claim text.